Psoriasis Pathophysiology Explained, From Keratinocyte Disease to TH17-Driven Inflammation

Psoriasis is no longer understood as a disorder of excessive keratinocyte proliferation alone. Advances over the past four decades have reclassified psoriasis as a complex, immune-mediated inflammatory disease dominated by TH17 and IL-23 signaling. This evolving understanding has directly shaped therapeutic development and clinical outcomes.

Evolution of Psoriasis Pathophysiology

Prior to the 1980s, psoriasis was conceptualized as a disease of keratinocyte dysfunction, based on the visible hyperproliferation of epidermal cells. Early therapies focused on suppressing cell turnover through topical retinoids, phototherapy, and antimetabolites such as methotrexate¹.

In the 1980s and 1990s, the dramatic efficacy of cyclosporine and TNF-α inhibitors reframed psoriasis as an immunologic disease, implicating T-cell activation and cytokine signaling¹,². Subsequent research identified the central role of IL-12 and TH1 pathways, followed by the discovery of the TH17 axis in the mid-2000s.

Current evidence supports psoriasis as a predominantly IL-23/IL-17-mediated disease, with contributions from TH1 and TH22 signaling³.

TH17 Cells and Cytokine Amplification

Dendritic cell activation in response to environmental and endogenous triggers promotes differentiation of naïve T cells into TH17 cells via IL-1β, IL-6, IL-23, and TGF-β signaling⁴. TH17 cells produce IL-17A, IL-17F, and IL-22, which act directly on keratinocytes to induce:

• Epidermal hyperproliferation
• Impaired terminal differentiation
• Increased antimicrobial peptide production
• Chemokine-mediated immune recruitment

Keratinocytes further amplify inflammation by producing cytokines and chemokines that sustain immune activation, creating a self-reinforcing inflammatory loop³.

Clinical Implications

This immunologic model explains:

• Chronic disease persistence
• Rapid relapse after treatment withdrawal
• The efficacy of targeted biologic therapies

It also clarifies why therapies targeting IL-17 and IL-23 achieve higher PASI 90 and PASI 100 response rates than earlier TNF-α inhibitors⁵.

Clinical Insight

Psoriasis severity reflects immune signaling intensity rather than epidermal dysfunction alone. Effective management requires understanding the upstream immune drivers shaping keratinocyte behavior.

References

1. Barker JNWN. The pathophysiology of psoriasis. Lancet. 1991;338(8761):227-230.
2. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med. 1995;332(9):581-589.
3. Yamanaka K, Yamamoto O, Honda T. Pathophysiology of psoriasis. J Dermatol. 2021;48(6):722-731.
4. Schmidt-Weber CB, Akdis M, Akdis CA. TH17 cells in immunology. J Allergy Clin Immunol. 2007;120(2):247-254.
5. Zhu X, Zhu J. CD4 T helper cell subsets. Int J Mol Sci. 2020;21(21):8011.